Puma Biotechnology (PBYI) Net Cash Flow (2011 - 2026)

Puma Biotechnology has reported Net Cash Flow for 16 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 205.7% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at -$26.9 million (down 95.72% YoY), and the FY2025 full-year result was -$39.6 million, down 157.62% from the prior year.
• Net Cash Flow for Q1 2026 stood at $6.5 million, up from -$23.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $25.2 million in Q3 2022, with the low at -$23.9 million in Q4 2025.
• Historically, Net Cash Flow has averaged -$2.2 million across 5 years, with a median of -$1.8 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow surged 229.9% — and 2025, when it sank 1321.47%.
• Puma Biotechnology's Net Cash Flow stood at -$1.8 million in 2022, then surged by 229.9% to $2.3 million in 2023, then slipped by 14.4% to $2.0 million in 2024, then slumped by 1321.47% to -$23.9 million in 2025, then surged by 127.38% to $6.5 million in 2026.
• The last three Net Cash Flow figures came in at $6.5 million (Q1 2026), -$23.9 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.